Spyre Therapeutics Inc (NASDAQ: SYRE) started the day on Wednesday, with a price increase of 4.34% at $37.48, before settling in for the price of $35.92 at the close. Taking a more long-term approach, SYRE posted a 52-week range of $8.43-$47.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -49.91%. Meanwhile, its Annual Earning per share during the time was 1.60%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 92.00%. This publicly-traded company’s shares outstanding now amounts to $50.92 million, simultaneously with a float of $42.22 million. The organization now has a market capitalization sitting at $1.91 billion. At the time of writing, stock’s 50-day Moving Average stood at $30.34, while the 200-day Moving Average is $30.94.
Spyre Therapeutics Inc (SYRE) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Spyre Therapeutics Inc’s current insider ownership accounts for 17.08%, in contrast to 95.75% institutional ownership. According to the most recent insider trade that took place on Oct 25 ’24, this organization’s Director sold 300 shares at the rate of 36.43, making the entire transaction reach 10,929 in total value, affecting insider ownership by 34,060.
Spyre Therapeutics Inc (SYRE) Earnings and Revenue Records
Spyre Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 92.00% and is forecasted to reach -3.93 in the upcoming year.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Let’s observe the current performance indicators for Spyre Therapeutics Inc (SYRE). It’s Quick Ratio in the last reported quarter now stands at 19.70. The Stock has managed to achieve an average true range (ATR) of 1.84.
In the same vein, SYRE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -15.45, a figure that is expected to reach -0.82 in the next quarter, and analysts are predicting that it will be -3.93 at the market close of one year from today.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
If we take a close look at the recent performances of Spyre Therapeutics Inc (NASDAQ: SYRE), its last 5-days Average volume was 0.4 million that shows plunge from its year to date volume of 0.51 million. During the previous 9 days, stock’s Stochastic %D was recorded 80.41% While, its Average True Range was 1.86.
Raw Stochastic average of Spyre Therapeutics Inc (SYRE) in the period of the previous 100 days is set at 96.41%, which indicates a major rise in contrast to 91.02% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 44.19% that was lower than 66.78% volatility it exhibited in the past 100-days period.
